Results 21 to 30 of about 2,699 (183)

Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 6, Page 2239-2242, June 2026.
Cliff ERS, McKeague S, Dickinson MJ.
europepmc   +2 more sources

DFT studies of metal oxide nanocluster as a possible drug delivery system for mechlorethamine [PDF]

BMC Chemistry
This study examined the adsorption of the mechlorethamine (ME) anti-cancer drug loaded upon Mg12O12 nanocage using DFT: B3LYP (6-31G* and 6-311G** basis set) and B3PW91 (6-31G* basis set) calculations.
Shahnaz Azari gharelar, Shiva Masoudi, Nasrin Masnabadi, Mohammad Hadi Ghasemi   +3 more
doaj   +2 more sources

Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data

Drug Design, Development and Therapy, 2018
Kendall Liner,1 Celeste Brown,2 Laura Y McGirt3 1Division of Dermatology, Medical College of Georgia at Augusta Health, Augusta, GA, USA; 2School of Medicine, University of North Carolina at Chapel Hill, Carolinas Medical Center, Charlotte, NC, USA ...
Liner K, Brown C, McGirt LY
doaj   +1 more source

Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series. [PDF]

Case Rep Dermatol Med
Background Mycosis fungoides (MF) is a subtype of T‐cell lymphoma that is characterised by the infiltration of malignant T cells into the skin. Treatment approaches usually include skin‐directed therapies for early‐stage disease and, additionally, systemic therapies for advanced stages.
Dobos G, Jonak C, Klespe KC, Wobser M, de Masson A, Hoffmann J, Mitteldorf C.   +6 more
europepmc   +2 more sources

Mechlorethamine Hydrochloride

Archives of Surgery, 1964
The use of chemotherapeutic agents as an adjunct to operative management of malignant disease is receiving considerable attention in current cancer research. Since the effects of these highly toxic drugs are not entirely limited to neoplastic tissue, however, knowledge of their effects on normal healing of wounds would be valuable.
C G, LONGENECKER, E T, KREMENTZ
openaire   +3 more sources

Mechlorethamine

, 2006
James L. Schardein, Orest T. Macina
core   +5 more sources

THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related ...
Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori   +2 more
doaj   +1 more source

Topical Mechlorethamine

Archives of Dermatology, 1977
Six patients with mycosis fungoides were treated with topical mechlorethamine hydrochloride for periods of two to four years. Clinical and histological studies for radiomimetic and radiodermatitis-like effects failed to demonstrate any abnormalities.
Norman M. Price
openaire   +3 more sources

Mechlorethamine [PDF]

, 2020
openaire   +2 more sources

A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)—A Retrospective Cohort Study

Frontiers in Medicine, 2021
Topical chlormethine yields high response rates in mycosis fungoides cutaneous T-cell lymphoma with early discontinuation often attributed to skin reactions.
Christiane Querfeld, Theresa Pacheco, Bradley Haverkos, Gary Binder, James Angello, Brian Poligone   +5 more
doaj   +1 more source